New evidence
Chewable Lactobacillus rhamnosus GG reached the nose and slashed nasal IL-13 in allergy patients — but this single early trial didn't test whether it works for anyone without allergic rhinitis.
This is the first solid evidence that a specific probiotic strain, delivered via a chewable tablet, can directly colonize the upper airways and locally reduce key inflammatory cytokines — but with only one study so far, the finding is a promising lead, not a settled fact.
In a placebo-controlled trial, people with hay fever who took a chewable form of this probiotic had significantly lower levels of interleukin-13 in their nasal passages (a driver of allergic inflammation) and lower salivary interleukin-4. The same study also found that the probiotic colonized the upper respiratory tract and was linked to reduced allergy symptoms, though those symptom results weren't reported with statistical significance — meaning the cytokine drop is the clearest signal, but the full picture for symptom relief is still fuzzy.
Where this fits in the evidence
This is among the first studies we've indexed on Lactococcus lactis L1A-23 for Reduced Pro-Inflammatory Cytokines — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- 2025-10-07
- Microbiology spectrum
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.